Organization (Industry)
DR. REDDY'S LABORATORIES LIMITED
ClinicalTrials.gov lists DR. REDDY'S LABORATORIES LIMITED as lead sponsor of 226 trials. It has 15 active development programs and 77 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo The Hindu Business Line, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers DR. REDDY'S LABORATORIES LIMITED: 226 lead-sponsored trials and 10 legal-entity registrations. Part of DR REDDYS LABORATORIES LTD.
Disease areas (46)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dyslipidemias | 8 |
| Hypoalphalipoproteinemias | 7 |
| Lecithin Cholesterol Acyltransferase Deficiency | 7 |
| Rosacea | 6 |
| Arthritis, Rheumatoid | 5 |
Showing 5 of 46 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 8 |
| 2016 | 3 |
Showing 10 of 26 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (15)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Experimental: Arm A: DRL_RI | Arthritis, Rheumatoid | Phase 3 | 1 |
| DRL_RI | Lymphoma | Phase 3 | 1 |
| DRL_RI | Lymphoma, Follicular | Phase 3 | 1 |
| DRL_RI | Lymphoma, Non-Hodgkin | Phase 3 | 1 |
| Arm B: Rituxan®/Mabthera® | Arthritis, Rheumatoid | Phase 3 | 1 |
Showing 5 of 15 active programs.
Approved assets (77)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Levofloxacin | 2 |
| OMEZ 40 | 1 |
| OMEZ 80 | 1 |
| Ketorolac Tromethamine | 1 |
| PANITUMUMAB | 1 |
Showing 5 of 77 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 88% hit target (n=8) | 14% on time (n=7) |
Journals published in (17)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The journal of headache and pain | 4 |
| BJOG : an international journal of obstetrics and gynaecology | 1 |
| BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 1 |
| Clinical drug investigation | 1 |
| Clinical medicine insights. Gastroenterology | 1 |
Showing 5 of 17 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 190 | 12 | 2025-10-07 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 59 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Tizanidine Tablets USP, 4 mg, 1000-Count bottle, Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Srikakulam - 532 409 India. NDC 55111-180-10 | Class II | 2023-06-21 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 125 | 2026-08-14 |
Manufacturing and distribution sites (22)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| DR. REDDY'S LABORATORIES LIMITED | Medchal-Malkajgiri, IN | FDA | |
| DR REDDY'S LABORATORIES LIMITED | Srikakulam, IN | EMA, FDA, Health Canada | |
| DR. REDDY'S LABORATORIES LIMITED | Nalgonda, IN | FDA | |
| DR. REDDY'S LABORATORIES LIMITED | Sangareddy, IN | FDA, Health Canada | |
| DR.REDDY'S LABORATORIES LIMITED | Medchal-Malkajgiri, IN | EMA, FDA, Health Canada |
Showing 5 of 22 sites.
Organization relationships (25)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Parexel | Uses vendor | 2 |
| Syneos Health (United States) | Uses vendor | 2 |
| Lupin Pharmaceuticals (United States) | Co sponsors trial with | 1 |
| Cipla (India) | Co sponsors trial with | 1 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 1 |
Showing 5 of 25 relationships.
Latest dated events (794)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-14 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-13 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-08-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 794 events.
Biomarker capability evidence (136)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Primary endpoint in a Phase 3 trial |
| BCL2A1 | Trial collaborator | Primary endpoint in a Phase 3 trial |
| CEACAM5 | Trial sponsor | Named in trial inclusion criteria |
| CEACAM5 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 136 evidence rows.
Biomarkers this organization publishes on (13)
Shown in this order: most publications first.
Showing 5 of 13 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.